PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
The Ebola outbreak in the Democratic Republic of Congo, known as Bundibugyo virus disease (BVD), is growing quickly. As of June 17, the World Health Organization reports 896 confirmed infections and 232 fatalities.
A new study, published in JAMA Network Open, suggests that women who are actively taking combined contraceptive pills may be more likely to experience binge eating. The study, led by researchers from Michigan State University, followed 422 women in the United States and Canada over 49 days across...
People who live in the same home share many of the same bacteria in their mouths and guts, according to a new study published in Cell Press Blue. "Who we decide to share our homes with can have a huge influence on our microbiomes, which has potential consequences for our health," commented first author...
Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic dysfunction-associated steatohepatitis or MASH, marking the first approval for the liver disease in the country. The approval...